Skip to main content

Table 4 Detailed analysis of therapy administered during the trial

From: Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer

  Chemotherapy Endocrine therapy Trastuzumab
ER status
 Negative 63 / 76 (83%) 3 / 76 (4%) 20 / 76 (26%)
 Positive 135 / 174 (78%) 50 / 174 (29%) 35 / 174 (20%)
PR status
 Negative 81 / 101 (80%) 13 / 101 (13%) 27 / 101 (27%)
 Positive 117 / 149 (79%) 40 / 149 (27%) 28 / 149 (19%)
HER2 status
 Negative 112 / 143 (78%) 34 / 143 (24%) 3 / 144 (2%)
 Positive 66 / 76 (87%) 7 / 76 (9%) 44 / 77 (57%)
Circulating tumor cells
  ≥ 5 CTCs / 7.5 ml 100 / 122 (82%) 25 / 122 (21%) 19 / 122 (16%)
  < 5 CTCs / 7.5 ml 94 / 123 (76%) 26 / 123 (21%) 34 / 123 (28%)
RAS p21
 Elevated 25 / 29 (86%) 2 / 29 (7%) 9 / 29 (31%)
 Non elevated 174 / 222 (78%) 51 / 222 (23%) 46 / 222 (21%)